Article
NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancer.
Journal of the National Cancer Institute - 1 Apr 2026
Williams Dylan, Patel Chandni, Murray Kate, Oldfield Lucy, Small Benjamin, Barrera Lawrence N, O'Sullivan Rachel, Birch-Ford James, Evans Anthony, Campbell Fiona, Perez-Mancera Pedro A, Halloran Christopher M, Palmer Daniel, Greenhalf William, Copple Ian M, Goldring Chris, Hackert Thilo, Jackson Richard, Neoptolemos John P, Springfeld Christoph, Büchler Markus W, Michalski Christoph W, Ghaneh Paula, Costello Eithne
Abstract excerpt
BACKGROUND: NAD(P)H quinone dehydrogenase 1 (NQO1), a detoxification enzyme regulated by the Nrf2 cytoprotective pathway, is overexpressed in pancreatic ductal adenocarcinoma (PDAC). NQO1 levels are also influenced by the C609T single-nucleotide polymorphism (SNP). We hypothesized that elevated N...
Topics
- NAD(P)H Dehydrogenase (Quinone)
- Pancreatic Neoplasms
- Humans
- Animals
- Deoxycytidine
- Gemcitabine
- Mice
- Polymorphism, Single Nucleotide
- NF-E2-Related Factor 2
